Chinese University of Hong Kong
Shatin, Hong Kong
Location contact
Alice Kong, FRCP(Edin), MD
SUB_INVESTIGATOR
Derek Xia, MD
SUB_INVESTIGATOR
Jenny Ho
CONTACT
Philip Chiu, FRCSEd(Gen), MD
SUB_INVESTIGATOR
Stephen Ng, FRCSEd(Gen)
CONTACT
NCT Number: NCT07376486
This study is designed to evaluate the efficacy and safety of endoscopic duodenal re-cellularization therapy using pulsed electric field in individuals with in patients with a recent diagnosis of type 2 diabetes mellitus (T2DM).
Trial opening soon.
Get Notified18 year–60 year
All sexes
Interventional
Not applicable
Shatin, Hong Kong
Alice Kong, FRCP(Edin), MD
SUB_INVESTIGATOR
Derek Xia, MD
SUB_INVESTIGATOR
Jenny Ho
CONTACT
Philip Chiu, FRCSEd(Gen), MD
SUB_INVESTIGATOR
Stephen Ng, FRCSEd(Gen)
CONTACT
This is a prospective, single-armed, feasibility study enrolling individuals with a recent diagnosis of type 2 diabetes. Participants will be followed for 6 months for the primary endpoint and 2 years in total.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The pulsENDO procedure utilizes the pulsENDO catheter to deliver non-thermal pulsed electric field to the duodenum to induce cell regeneration. The catheter is introduced to the duodenum through the mouth using a guide wire and the therapy is applied to treat the duodenum under endoscopic visualisation, starting from D4 and repeated proximally. Approximately 10-18 cm of axial length of the duodenum is treated.
Time frame: 6 months post-procedure
Proportion of participants with HbA1c ≤6.5% without glucose lowering drugs
Time frame: 24 months post-procedure
Change in HbA1c (%) from baseline to Month 24
Time frame: 24 months post-procedure
Percent total body weight loss (%TBWL) from baseline to Month 24
Time frame: within 30 days post-procedure
Adverse events relating to endoscopic intervention, graded according to the Common Terminology Criteria for Adverse Events (CTCAE)
Time frame: 24 months post-procedure
Changes in body fat percentage - measured by bioelectrical impedance analysis from baseline to Month 24
Time frame: 24 months post-procedure
measured by 36-Item Short Form Survey (SF-36) questionnaire - (score 0:worst - 100:best) from baseline to Month 24
Time frame: 24 months post-procedure
level from baseline to Month 24
Contact information is provided by the study sponsor or research team.
Chinese University of Hong Kong
Other
Duodenal Recellularization Via Electroporation Therapy as an Early Treatment for Type 2 Diabetes Mellitus (DREAM-1 Study)
Acronym: DREAM-1
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07706088
Diabete Mellitus, Diabetes Mellitus
View Trial DetailsNCT07676214
Body Weight, Cardiovascular Diseases
View Trial DetailsNCT07609381
Arterial Occlusive Diseases, Arteriosclerosis
Calgary, Alberta, Canada
View Trial DetailsNCT07607015
Diabete Mellitus, Diabetes Mellitus
View Trial Details